Therapeutic Vaccines for Hypertension: a New Option for Clinical Practice
- 77 Downloads
Purpose of Review
Vaccines are commonly used as preventive methods, primarily against infectious diseases. The goal of our study is to develop the therapeutic vaccine for hypertension.
We and others recently reported that an angiotensin II (AngII) vaccine for hypertension successfully attenuated elevated blood pressures in an animal model without any immunogenic side effects. In this system, an immunogenic molecule (i.e., KLH) with adjuvants provides an antigen that supports the activation of helper T cells. In addition, pretreatment with the AngII vaccine exerts neuroprotective effects in a cerebral ischemia model and cardioprotective effects in a myocardial infarction model. In the early phase of clinical trial, the administration of an AngII vaccine (AngQb-Cyt006) successfully decreased blood pressure in hypertensive patients with the increase of anti-AngII antibody titer.
Increasing the effectiveness of drug adherence interventions in the clinical setting may have a large impact on the health of the population, which can be improved by using successful therapeutic vaccines. In this review, we describe the concept of therapeutic vaccines for hypertension and future directions for therapeutic vaccines.
KeywordsVaccine Antibody Angiotensin II
All of the authors contributed to writing the manuscript and have read and approved the final version of the manuscript.
Compliance with Ethical Standards
Conflict of Interest
The Department of Health Development and Medicine was financially supported by Daicel, Mitsubishi-Tanabe, AnGes, and Funpep. The Department of Clinical Gene Therapy is financially supported by Novartis, AnGes, Shionogi, Boeringher, Fancl, Saisei Mirai Clinics, Rohto, and Funpep.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 6.Nakagami F, Koriyama H, Nakagami H, Osako MK, Shimamura M, Kyutoku M, et al. Decrease in blood pressure and regression of cardiovascular complications by angiotensin II vaccine in mice. PLoS One. 2013;8(3):e60493. https://doi.org/10.1371/journal.pone.0060493.CrossRefPubMedPubMedCentralGoogle Scholar
- 7.• Wakayama K, Shimamura M, Suzuki JI, Watanabe R, Koriyama H, Akazawa H, et al. Angiotensin II peptide vaccine protects ischemic brain through reducing oxidative stress. Stroke. 2017;48(5):1362–8. Ang II vaccination exerts neuroprotective and antioxidative effects in cerebral ischemia in permanent middle cerebral artery occlusion model in rats, by penetration of anti-Ang II antibodies into ischemic brain lesion. CrossRefPubMedGoogle Scholar
- 8.• Watanabe R, Suzuki JI, Wakayama K, Maejima Y, Shimamura M, Koriyama H, et al. A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction. Sci Rep. 2017;7:43920. Treatment with Ang II vaccine significantly suppressed post-myocardial infarction cardiac dysfunction in rats and Ang II-induced remodeling-associated signaling in cardiac fibroblasts. CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Michel JB, Sayah S, Guettier C, Nussberger J, Philippe M, Gonzalez MF, et al. Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin. Circulation. 1990;81(6):1899–910. https://doi.org/10.1161/01.CIR.81.6.1899.CrossRefPubMedGoogle Scholar
- 14.Gardiner SM, Auton TR, Downham MR, Sharp HL, Kemp PA, March JE, et al. Active immunization with angiotensin i peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin i in conscious rats. Br J Pharmacol. 2000;129(6):1178–82. https://doi.org/10.1038/sj.bjp.0703178.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Tissot AC, Maurer P, Nussberger J, Sabat R, Pfister T, Ignatenko S, et al. Effect of immunisation against angiotensin ii with cyt006-angqb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet. 2008;371(9615):821–7. https://doi.org/10.1016/S0140-6736(08)60381-5.CrossRefPubMedGoogle Scholar